Cabanib 60 mg (Cabozantinib), general Cometriq is a traditional drug used to treat metastatic medullary thyroid cancer (MTC). This drug blocks the action of a particular enzyme from working which helps to decelerate or stop the spread of cancer cells.
Cabanib ( General Cabozantinib) is manufactured by Drug InternationalLtd. in Bangladesh.
Have to take orally formerly a day on an empty stomach ( Don’t eat for at least 2 hours ahead and at least 1 hour after taking the cure)
The most common adverse responses are
Dizziness, diarrhea, nausea, puking, mouth blisters, constipation, stomach pain, frazzle, weakness, weight loss, dropped appetite, taste changes, hoarseness, and lightening of hair color.
The below information comes from the Internet. Please consult with the croaker for medical advice.